The effects of orally administered erythromycin propionate have been observed in 105 patients. Most of them took it four times a day or every six hours in one or two capsules containing 0.25 Gm., and in a few cases this medication was continued as long as two months. The diseases treated were particularly those caused by Staphylococcus aureus, and the series included cases of pustular acne, furuncles, carbuncles, and pyodermas. Good results were obtained in 98 patients, 10 of whom had previously failed to respond to other forms of chemotherapy. Only eight patients had side-effects such as anorexia or vomiting, and diarrhea occurred in but one patient. This derivative, erythromycin propionate, has the advantage over the parent compound in that it produces higher concentrations in the blood after oral ingestion.
Smith IM, Soderstrom WH. CLINICAL EXPERIENCE WITH A NEW ERYTHROMYCIN DERIVATIVE, ERYTHROMYCIN PROPIONATE: REPORT OF ONE HUNDRED FIVE CASES. JAMA. 1959;170(2):184–188. doi:10.1001/jama.1959.03010020042013
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: